ReviewAmerican journal of clinical dermatology2024
Lichen Planus: What is New in Diagnosis and Treatment?
Review in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- [Pruritus-strong predictor of treatment response in lichen planus pigmentosus inversus].Dermatologie (Heidelberg, Germany) · 2026Pooled it
- Mucoadhesive Drug Delivery Systems for Oral Chronic Inflammatory Mucosal Diseases. The Future is Already Present. A Systematic Review.Oral diseases · 2026Pooled it
- Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives.Experimental dermatology · 2025Pooled it
- The role of skin microbiota in lichen planus from a Mendelian randomization perspective.Archives of dermatological research · 2025Pooled it
- Ocular manifestations of lichen planus: a comparative analysis of tear function, choroidal thickness, and retinal parameters.BMC ophthalmology · 2026Article
- Successful treatment of generalized lichen planus with deucravacitinib monotherapy.JAAD case reports · 2026Article
- Microneedle technology integrated with diverse therapeutic modalities for hair regrowth in alopecia.Acta pharmaceutica Sinica. B · 2026Review
- Leukemia cutis as the first manifestation of acute myeloid leukemia.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Regenerative Scalp Preparation With Stromal Vascular Fraction and Platelet-Rich Fibrin Prior to Hair Transplantation in Lichen Planus: A Case Report.Clinical case reports · 2026Article
- Evidence-based review and clinical practice recommendations for the diagnosis and management of common oral mucosal lesions.World journal of experimental medicine · 2026Review
- Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases.Biomedicines · 2026Review
- Lichen planus autoimmune comorbidities: A retrospective case control study.Dermatology online journal · 2026Article
- Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report.Frontiers in medicine · 2026Article
- Case Report: Sequential multi-stage dermoscopic evolution of hypertrophic lichen planus in a patient with varicose veins.Frontiers in medicine · 2026Article
- Article
- Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.Antibodies (Basel, Switzerland) · 2025Review
- When Classic Signs Deceive: A Widespread Papulosquamous Eruption in Skin of Colour.Dermatopathology (Basel, Switzerland) · 2025Article
- Efficacy of Dupilumab in a Young Woman with Refractory Cutaneous Lichen Planus: A Case-Based Review.Diseases (Basel, Switzerland) · 2025Review
- Lichen Planus: A Cross-Sectional Evaluation of US Dermatologists' Comorbidity Screening and Management Patterns.Dermatology and therapy · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus (LP), an idiopathic, multifaceted chronic inflammatory disease with a heterogeneous clinical presentation, affects approximately 0.5-1% of the population. The various clinical manifestations of LP fall into three broad categories, namely cutaneous, appendageal, and mucosal, with further subclassification depending on the morphology and distribution patterns of individual lesions. There is mounting evidence that LP has systemic associations, including autoimmune conditions, glucose intolerance, dyslipidemia, and cardiovascular disorders. Cutaneous hypertrophic and mucosal forms of LP are at a heightened risk for malignant transformation. Familiarity with these potential associations in conjunction with long-term follow-up and regular screening could lead to a timely diagnosis and management of concomitant conditions. In addition, the frequent quality of life (QoL) impairment in LP underscores the need for a comprehensive approach including psychological evaluation and support. Several treatment strategies have been attempted, though most of them have not been adopted in clinical practice because of suboptimal benefit-to-risk ratios or lack of evidence. More recent studies toward pathogenesis-driven treatments have identified Janus kinase inhibitors such as tofacitinib, phosphodiesterase-4 inhibitors such as apremilast, and biologics targeting the interleukin-23/interleukin-17 pathway as novel therapeutic options, resulting in a dramatic change of the treatment landscape of LP. This contemporary review focuses on the diagnosis and management of LP, and places emphasis on more recently described targeted treatment options.
Indexed as
Identifiers
38982032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.